Afrezza: Fast-Acting Inhaled Insulin

No Thumbnail Available

Links to Files

https://ezproxy.stevenson.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=rzh&AN=107830773&site=eds-live&scope=site

Permanent Link

http://dx.doi.org/10.1097/01.NAJ.0000454844.50727.76
 http://hdl.handle.net/11603/5650

Collections

Stevenson University Faculty and Staff Works

Author/Creator

Author/Creator ORCID

Date

2014-10

Type of Work

journal articles
Text

Department

Sandra R. Berman School of Nursing and Health Professions

Program

Nursing

Citation of Original Publication

Aschenbrenner, D. S. (2014). Afrezza: Fast-acting inhaled insulin. American Journal Of Nursing, 114(10), 22-23. doi:10.1097/01.NAJ.0000454844.50727.76

Rights

Subjects

Abstract

Afrezza (insulin human) is a newly approved fast-acting inhaled insulin. It can be used in treating type 1 diabetes when added to a long-acting insulin; in studies, patients with type 2 diabetes used it in combination with oral antidiabetic therapy. Afrezza will be available in 2015. Afrezza is taken before meals using a small, specially designed inhaler. Patients should be carefully assessed for lung disease prior to starting Afrezza therapy. Chronic obstructive pulmonary disease and asthma are contraindications to use. Lung function can deteriorate after therapy begins.